Novartis AG (NVSEF)
OTCMKTS · Delayed Price · Currency is USD
127.81
0.00 (0.00%)
Oct 27, 2025, 8:00 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $14.36B in the quarter ending September 30, 2025, with 9.00% growth. This brings the company's revenue in the last twelve months to $56.37B, up 12.88% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
56.37B
Revenue Growth
+12.88%
P/S Ratio
4.24
Revenue / Employee
742.88K
Employees
75,883
Market Cap
239.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| LogicMark | 10.40M |
| Northwest Biotherapeutics | 1.09M |
Novartis AG News
- 22 hours ago - Novartis completes acquisition of Tourmaline Bio - GlobeNewsWire
- 1 day ago - Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue - Invezz
- 1 day ago - Novartis looking to add more medicines to direct to patient platform, CEO says - Reuters
- 1 day ago - Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done' - CNBC
- 1 day ago - Novartis Posts Higher Net Profit as Key Drugs Lift Sales - WSJ
- 1 day ago - Novartis announces expiration of Tourmaline Bio tender offer - GlobeNewsWire
- 1 day ago - Novartis Q3 operating income up 6% on new drug sales - Reuters
- 1 day ago - Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance - GlobeNewsWire